Right ventricular dysplasia: management and treatment in light of current evidence
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare cardiovascular disease that predisposes to ventricular arrhythmias potentially leading to sudden cardiac death (SCD). ARVC varies considerably with multiple clinical presentations, ranging from no symptoms to cardiac arrhythmias to SCD...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Greater Baltimore Medical Center
2018-05-01
|
| Series: | Journal of Community Hospital Internal Medicine Perspectives |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20009666.2018.1472513 |
| _version_ | 1797967172864049152 |
|---|---|
| author | Amr Idris Syed Raza Shah Ki Park |
| author_facet | Amr Idris Syed Raza Shah Ki Park |
| author_sort | Amr Idris |
| collection | DOAJ |
| description | Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare cardiovascular disease that predisposes to ventricular arrhythmias potentially leading to sudden cardiac death (SCD). ARVC varies considerably with multiple clinical presentations, ranging from no symptoms to cardiac arrhythmias to SCD. ARVC prevalence is not well known, but the estimated prevalence in the general population is 1:5000. Diagnosis of ARVC can be made by using the Revised European Society of Cardiology criteria for ARVC that includes ventricular structural and functional changes, ECG abnormalities, arrhythmias, family and genetic factors. The management of ARVC is focused on prevention of lethal events such as SCD. Implantable cardioverter defibrillator placement is the only proven mortality benefit in treatment of ARVC. Other treatment strategies include medications such as beta blockers and antiarrhythmics, radiofrequency ablation, surgery, cardiac transplantation, and lifestyle changes. All these interventions help in symptomatic treatment but none of them have proved to decrease mortality rates. ARVC is a progressive disease that leads to SCD if not treated appropriately. Management of these diseases has been a challenge for physicians. With the advent of technology and many new drugs/devices under clinical investigation, this might change in the future. However, while advances in technologies have helped elucidate many aspects of these diseases, many mysteries still remain of this unique disease. With continued research, we can expect more cost-effective and patient-friendly drug therapies and ablation techniques to be developed in the near future. |
| first_indexed | 2024-04-11T02:25:57Z |
| format | Article |
| id | doaj.art-77c286048a2849839842cf6db74713cd |
| institution | Directory Open Access Journal |
| issn | 2000-9666 |
| language | English |
| last_indexed | 2024-04-11T02:25:57Z |
| publishDate | 2018-05-01 |
| publisher | Greater Baltimore Medical Center |
| record_format | Article |
| series | Journal of Community Hospital Internal Medicine Perspectives |
| spelling | doaj.art-77c286048a2849839842cf6db74713cd2023-01-02T22:39:14ZengGreater Baltimore Medical CenterJournal of Community Hospital Internal Medicine Perspectives2000-96662018-05-018310110610.1080/20009666.2018.14725131472513Right ventricular dysplasia: management and treatment in light of current evidenceAmr Idris0Syed Raza Shah1Ki Park2University of Central Florida (Gainesville)University of Central Florida (Gainesville)University of FloridaArrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare cardiovascular disease that predisposes to ventricular arrhythmias potentially leading to sudden cardiac death (SCD). ARVC varies considerably with multiple clinical presentations, ranging from no symptoms to cardiac arrhythmias to SCD. ARVC prevalence is not well known, but the estimated prevalence in the general population is 1:5000. Diagnosis of ARVC can be made by using the Revised European Society of Cardiology criteria for ARVC that includes ventricular structural and functional changes, ECG abnormalities, arrhythmias, family and genetic factors. The management of ARVC is focused on prevention of lethal events such as SCD. Implantable cardioverter defibrillator placement is the only proven mortality benefit in treatment of ARVC. Other treatment strategies include medications such as beta blockers and antiarrhythmics, radiofrequency ablation, surgery, cardiac transplantation, and lifestyle changes. All these interventions help in symptomatic treatment but none of them have proved to decrease mortality rates. ARVC is a progressive disease that leads to SCD if not treated appropriately. Management of these diseases has been a challenge for physicians. With the advent of technology and many new drugs/devices under clinical investigation, this might change in the future. However, while advances in technologies have helped elucidate many aspects of these diseases, many mysteries still remain of this unique disease. With continued research, we can expect more cost-effective and patient-friendly drug therapies and ablation techniques to be developed in the near future.http://dx.doi.org/10.1080/20009666.2018.1472513Arrhythmogenic right ventricular cardiomyopathyICDSCD |
| spellingShingle | Amr Idris Syed Raza Shah Ki Park Right ventricular dysplasia: management and treatment in light of current evidence Journal of Community Hospital Internal Medicine Perspectives Arrhythmogenic right ventricular cardiomyopathy ICD SCD |
| title | Right ventricular dysplasia: management and treatment in light of current evidence |
| title_full | Right ventricular dysplasia: management and treatment in light of current evidence |
| title_fullStr | Right ventricular dysplasia: management and treatment in light of current evidence |
| title_full_unstemmed | Right ventricular dysplasia: management and treatment in light of current evidence |
| title_short | Right ventricular dysplasia: management and treatment in light of current evidence |
| title_sort | right ventricular dysplasia management and treatment in light of current evidence |
| topic | Arrhythmogenic right ventricular cardiomyopathy ICD SCD |
| url | http://dx.doi.org/10.1080/20009666.2018.1472513 |
| work_keys_str_mv | AT amridris rightventriculardysplasiamanagementandtreatmentinlightofcurrentevidence AT syedrazashah rightventriculardysplasiamanagementandtreatmentinlightofcurrentevidence AT kipark rightventriculardysplasiamanagementandtreatmentinlightofcurrentevidence |